Upon infection of susceptible cells and integration into the host genome, transcription of the human immunodeficiency virus type 1 (HIV-1) is dependent on the concerted action of the cellular transcription machinery and of the viral Tat transactivator protein. Tat acts as an extremely powerful activator of viral gene expression. The protein binds to a bulge sequence within TAR, a highly structured RNA element located at the 5Ј end of all viral transcripts (8) , and acts by a dual mechanism. From one side, it increases the levels of transcriptional elongation, by augmenting the processivity of RNA polymerase II through the interaction with protein complexes possessing protein kinase activity and phosphorylating the carboxyl-terminal domain of the large subunit of the polymerase (13, 21, 36, 43, 46) . On the other side, the protein also acts at the level of transcriptional initiation, by increasing the rate at which the RNA polymerase II starts transcription (14) . We (33) and others (5, 27) have recently demonstrated that the latter function of Tat is mediated by the specific interaction of Tat with the nuclear factor p300-CREB binding protein and by the recruitment of this acetyltransferase to the viral long terminal repeat (LTR) for chromatin remodeling.
Besides the above-mentioned interactions of cellular proteins with Tat, which require an intact TAR element, experimental evidence indicates that an additional transcriptional function of the protein also occurs in a TAR-independent manner, provided that the enhancer region of the LTR is intact (1, 6, 7, 25, 35) . This region contains two tandemly arranged binding sites (B sites) for the dimeric transcription factors composed of several combinations of members of the Rel/ NF-B family of polypeptides (for a review, see reference 3). The predominant complex binding to the LTR B sites in activated cells is NF-B (p50-p65 heterodimer). In unstimulated cells, NF-B is retained in the cytoplasm through the interaction with inhibitor proteins belonging to the IB family.
Activation of NF-B occurs through phosphorylation and proteolysis of the IB inhibitor, with subsequent translocation of the active factor into the nucleus, where it can bind to its cognate binding sites (26) . Maximal activation of the HIV LTR requires the concerted action of Tat and of cellular proteins binding to the B sites (1, 10, 19, 32, 44) . Accordingly, Tatmediated activation of the HIV-1 LTR in Jurkat T cells is strongly inhibited by a degradation-resistant IB-␣ mutant (24) .
Tat itself is able to activate nuclear translocation of NF-B (11, 16, 44) . We have observed that treatment of T-lymphocytic, monocytic, and epithelial cells with recombinant Tat results in a rapid and transient nuclear translocation of NF-B which parallels transcriptional activation of the proviral LTR (16) .
To address the study of the functional domains of the Tat protein involved in the activation of NF-B, we obtained a series of constructs bearing deletions or point mutations in some of the relevant portions of the protein. A schematic representation of these constructs is presented in Fig. 1 . They include the wild-type Tat proteins of 101 amino acids (aa) (present in most primary HIV isolates) and of 86 aa (retaining full activity and present in the prototype laboratory strain HXB2) and mutated derivatives of the latter protein having a deletion of the acidic, N-terminal domain [Tat 86⌬ ], mutations of the cysteines at positions 22, 25, and 27 to alanines [Tat 86 C(22-27)A], and mutations of the arginines in the basic region at positions 49, 52, 53, 55, 56, and 57 to alanines [Tat 86 R(49-57)A]. The construction and purification of these recombinant Tat proteins have been already described (16, 33) ; all these mutations completely knock out the ability of the protein to trans-activate the LTR (not shown).
These mutants were tested either as recombinant proteins obtained as glutathione S-transferase fusions or after transfection of the corresponding expression vectors. In the former case, recombinant Tat was delivered to the cells by lipofection, as already described (16, 33) . Under these conditions, the protein rapidly enters the cells through an endosome-mediated pathway and subsequently escapes from the endosomes and enters the nucleus, where it displays its transactivation capacity.
Wild-type Tat and mutant proteins were delivered into HL3T1 cells (containing an integrated LTR-chloramphenicol acetyltransferase [CAT] cassette, the kind gift of B. Felber [20] ), and nuclear extracts were prepared according to the microscale preparation protocol described by Li et al. (31) and used in gel retardation assays to monitor the binding activity to a B site oligonucleotide (17) . As shown in Fig. 2A , NF-B induction appeared considerably reduced when the Tat protein mutated in the basic domain was used, while the other mutations did not have any remarkable effect.
We also examined whether the effects of mutations in the basic region could be observed by transfection of an expression vector for the protein. Transfections were performed by using Lipofectin (Gibco BRL Life Technologies Ltd., Paisley, Scotland) in accordance with the procedure suggested by the manufacturer. To reduce the basal level of NF-B in cycling HL3T1 cells (shown in Fig. 2, lane 7) , 16 h after transfection cells were put in 0.5% serum. Under these conditions, NF-B induction could be obtained by the expression vectors for Tat 86 and Tat 86⌬ to levels comparable to those obtained by serum addition (Fig. 1B) . On the contrary, transfection of Tat 86 R(49-57)A did not result in the induction of nuclear translocation of NF-B.
The experiments described above indicate that the basic domain of Tat is essential for NF-B induction. Interestingly, this domain has been reported to interact with the human RNA-dependent protein kinase PKR both in vitro (12) and in vivo (34) . This protein, also referred to as DAI, P1 kinase, and p68 kinase, is a serine/threonine kinase that is induced by interferon and is activated in the presence of double-stranded RNA, polyanions, and some structured single-stranded RNA (reviewed in reference 40). Activation of PKR leads to its autophosphorylation and to the consequent phosphorylation of its cellular targets, which include eukaryotic initiation factor 2 (eIF2) (9, 41) and IB-␣ (28), with consequent inhibition of protein synthesis and activation of NF-B translocation, respectively.
Given these considerations, we addressed the question of . Sixteen hours after transfection, serum concentration was lowered to 0.5% for an additional 24 h. Nuclear extracts were prepared and used in a gel retardation assay as described above. Two hours before harvesting, 10% serum was added to control cells (lane 2).
(45), the kind gift of B. Williams. We first checked whether Tat could induce NF-B in mouse cells. Mouse NIH 3T3 fibroblasts were transfected with expression plasmids coding for Tat 101; for activated Rac, a member of the family of small GTP binding proteins shown to trigger NF-B nuclear translocation (37) (the kind gift of Alan Hall); and for PKR, donated by B. Williams. Transfected and mock-transfected cells were serum starved for 24 h to reduce the level of constitutive NF-B present in cycling 3T3 cells, as described previously (37) . After serum starvation, rich medium was added to one aliquot of mock-transfected cells to obtain a positive control for NF-B nuclear translocation. Nuclear extracts were prepared and utilized for band-shift assays with the oligonucleotide probe specific for NF-B. As shown in Fig. 3A, NF-B 
Contrary to what was observed in NIH 3T3 fibroblasts, in Pkr 0/0 mouse cells neither Tat nor PKR alone could trigger NF-B activation (Fig. 3B, lanes 1 and 2) , while cotransfection of the two plasmids resulted in a strong synergistic effect (lane 3), similar to the one obtained by serum addition (lane 4). The activated factor observed by gel retardation assays in these cells was identified as NF-B containing the p50 and p65 subunits, since p50 antibody supershifted and p65 antibody abolished the complex (Fig. 3C) . Supershift assays were performed with NF-B p50 and p65 polyclonal antibodies (Santa Cruz Biotechnology, Santa Cruz, Calif.) by preincubating the nuclear extracts with 2 g of the antibody in the reaction buffer for 30 min prior to the gel retardation assays.
The above results clearly indicate that PKR is involved in Tat-induced activation of NF-B in mouse cells. The next step was to test whether this functional interaction also affects the transcriptional properties of Tat. For this purpose, we studied the role of Tat and PKR in the activation of transcription from a transfected LTR-CAT cassette in mouse cells lacking a functional PKR as well as in control NIH 3T3 cells. Cell extracts were prepared 48 h after transfection, and CAT assays were performed according to standard protocols (39) after normalization for transfection efficiency.
The results are shown in Fig. 4 . As expected, the effects of Tat on LTR-driven transcription in mouse cells are not as dramatic as in human cells (2, 4) . Therefore, the amount of Tat plasmid that was transfected was 10 times higher (5 g of DNA/10-cm plate) than the one we generally use for human cells. Under these conditions, Tat considerably enhances the transcription driven by the LTR in NIH 3T3 cells, while PKR does not have any effect (Fig. 4A) . In PKR knockout cells (Fig.  4B ) the transcriptional effect of Tat is impaired with respect to control cells, but it can be fully restored by cotransfection of a wild-type PKR expression plasmid. Altogether, the data described above demonstrate that the functions of PKR are required for NF-B nuclear translocation and LTR transcription activation by Tat in a murine system. Next, it was important to address the question of whether PKR plays a similar role in human cells. For this purpose, we exploited the properties of a series of dominant-negative mutants of different proteins physiologically involved in different pathways of NF-B activation. These proteins included, besides PKR, a set of small GTP binding proteins of the Rho family (Ras, RhoA, Rac1, and Cdc42), which are known reg- 3) were transfected with the empty vector pCDNAIII. After 16 h, cells were serum starved (0.5% serum) for 24 h to lower the endogenous NF-B levels (37) . Gel retardation assays were performed with 7.5 g of nuclear extract by using an NF-B-specific oligonucleotide probe. Two hours before cells harvesting, 10% serum was added to control cells in lane 2. ulators of different protein kinases and act as potent activators of NF-B in various cell types (37) .
For each of these factors (37), as well as for PKR (29), mutants having a trans-dominant-negative effect on the wildtype proteins have been described. Expression vectors for dominant-negative PKR, Ras, and Rac were kindly donated by B. Williams, C. J. Marshall, and A. Hall, respectively. Dominant negatives for RhoA and CDC42 were the kind gift of G. Bokoch.
These vectors were cotransfected with Tat in human epithelial HL3T1 and monocytic BF24 cells (both of which contain an integrated LTR-CAT cassette [20, 42] ) and in T-lymphocytic Jurkat cells together with an LTR-CAT plasmid. In all these cell lines, the PKR dominant-negative mutant caused a net decrease in Tat-mediated activation of LTR-driven transcription (Fig. 5A, B, and C) . On the contrary, dominant negatives of Ras, Rac1, RhoA, and Cdc42 did not have any significant effect. As control, all the dominant-negative mutants were previously checked in cotransfection experiments in Jurkat cells for their ability to prevent the activation of the HIV-1 LTR by their respective wild-type counterparts (not shown).
The inhibitory effect of the PKR dominant-negative construct on Tat transactivation was mediated in cis by the enhancer region of the LTR. As shown in Fig. 6 , when the vector expressing Tat 101 was cotransfected in HeLa cells together with the PKR dominant-negative construct, transactivation from the wild-type LTR was reduced, while it was unaffected from an LTR promoter bearing the deletion of the NF-B sites (30) .
Altogether the experimental data reported above indicate that PKR is involved in Tat transactivation of the LTR both in rodent and in human cells through the activation of NF-B. Following different experimental strategies, over the last few years, several laboratories have suggested that a complex interplay exists between Tat, TAR, and PKR, although the results obtained have often been controversial. Some reports showed that TAR activates PKR, resulting in trans inhibition of translation (18), while others demonstrated that PKR-TAR interaction had a negative effect on activation of the kinase (22, 23) . Also controversial are the findings that the levels and the activity of PKR are decreased (38) , increased (15), or unaffected (34) in HIV-1-infected and in Tat-expressing cells. These conflicting data are difficult to reconcile and are likely the results of the different experimental settings in which they were obtained. As far as Tat and PKR are concerned, two independent laboratories have recently shown that a physical interaction exists between the two proteins both in vitro and in vivo and that this interaction requires the integrity of the basic domain of Tat (12, 34) . This is the same domain that we found to be essential for the activation of NF-B in our experiments. However, it should be pointed out that the same laboratories have indicated, by in vitro studies, that Tat behaves as an inhibitor of PKR activation and as a competitive substrate for phosphorylation, in apparent contradiction with the functional positive role of the PKR-Tat interplay that we are suggesting here. In this respect, we believe that the conditions for in vitro functional studies of the kinase are likely to be considerably different from those found within the cells, where the relative concentrations of PKR, TAR, Tat, and accessory factors are not easily quantifiable and might vary during the course of infection. As an alternative explanation, we cannot rule out the possibility that the functional requirement of PKR for Tatmediated NF-B activation, which clearly stems from the set of our experiments, is not directly dependent on the PKR-Tat protein-protein interaction but is mediated by an unidentified intermediate pathway.
The results presented in this work suggest that both Tat 101, Tat 86, and Tat 72 (one exon; results not shown) are able to activate NF-B through the PKR pathway, both in rodent and human cells, and that this pathway requires the integrity of the basic domain of the protein. Thus, this mechanism appears to be clearly different from the one proposed by Westendorp and collaborators (44) , which requires the second exon of the protein and involves the repression of the Mn-dependent superoxide dismutase and the subsequent alteration of the redox state of the cell. An alternative pathway proposed to explain NF-B activation by Tat is the induction of expression of the tumor necrosis factor alpha (TNF-␣) gene and the subsequent FIG. 4 . PKR is functionally required for Tat transactivation of the LTR promoter in mouse fibroblasts. NIH 3T3 mouse cells and primary mouse fibroblasts (panels A and B, respectively) from PKR knockouts were transiently transfected with a reporter plasmid containing the LTR linked to the CAT gene. Five micrograms of Tat 101 and/or 5 g of PKR expression constructs was cotransfected, as indicated. The empty vector pCDNAIII was added in order to keep constant the amount of transfected DNA. Forty-eight hours after transfection, cell extracts were prepared and monitored for CAT activity after normalization for transfection efficiency. The bars show the percentage of chloramphenicol acetylation obtained with each extract; the data are the averages of three independent experiments, and the standard deviations are indicated. Standardization for transfection efficiency was also obtained by cotransfection of 0.5 g of a luciferase expression vector per 60-mm plate.
activation of NF-B through the TNF-␣ receptor-mediated signaling mechanism (11) . Again, this mechanism is quite distinct from the one suggested by the data presented here, since TNF-␣ signals responsive promoters in both PKR ϩ/ϩ and PKR 0/0 cells, indicating that this cytokine utilizes a largely non-PKR-dependent transduction pathway (29) .
It is conceivable that all the above-mentioned molecular processes of Tat-induced NF-B activation could operate in FIG. 5 . Dominant-negative PKR impairs LTR activation induced by Tat. HL3T1, BF24, and Jurkat cells (panels A, B, and C, respectively) were transfected with 2.5 g of pCDNAIII empty vector (first lanes of each panel) or with 500 ng of Tat 101 expression vector and 2 g of the dominant-negative mutant cDNAs for Ras (plasmid Ras N17), Rac (Rac N17), RhoA (Rho T19N), CDC42 (Cdc42 T17N), and PKR (PKR-M) as indicated. Jurkat cells were also cotransfected with 1 g of an LTR-CAT-containing plasmid. Twenty hours after transfection, cell extracts were prepared and used for CAT assays after normalization for transfection efficiency. The results are the mean values from three independent experiments, with error bars indicating standard deviations. different cell types and under different conditions. While it is difficult to rank the relative importance of these mechanisms, we would like to point out that in murine fibroblasts lacking PKR the induction of NF-B nuclear translocation by Tat is almost completely impaired, thus suggesting that, at least in this cell type, the presence of functional PKR is likely to be crucial for this function.
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